A Centers for Disease Control and Prevention (CDC) advisory committee is recommending moderate-to-severe immunocompromised individuals receive an mRNA COVID-19 booster dose. The Advisory Committee on Immunization Practices held the vote Friday, a day after the FDA expanded emergency use of Pfizer-BioNTech and
The U.S. Food and Drug Administration expanded emergency use of Pfizer-BioNTech and Moderna’s COVID-19 vaccines to authorize a booster shot for certain immunocompromised patients. HIV and cancer patients, organ transplant recipients and those taking immunosuppressant drugs comprise about 2.7% of the U.S.
Ahead of an anticipated FDA authorization for COVID-19 booster vaccines among certain individuals with weakened immune systems, the American Cancer Society has voiced full support behind efforts to offer cancer patients greater protection against COVID-19. CLICK HERE TO FIND A COVID-19 VACCINE
The Food and Drug Administration says it will soon reveal information on COVID booster shots for immunocompromised people who remain vulnerable to the virus and its variants. “The FDA is closely monitoring data as it becomes available from studies administering an additional
Immunocompromised patients fully vaccinated against COVID-19 should continue to wear face masks, maintain 6 feet of distance and take preventive steps as researchers continue to weigh booster doses in the fragile population. Dr. Sara Oliver, member of the CDC’s Epidemic Intelligence Service